Biowave Corporation appears in FDA 510(k) records as the applicant for BioWave BioWraps under product code GXY, with a substantially equivalent decision dated November 5, 2026. The same device family was cleared earlier under K203158, dated July 8, 2021, where the FDA letter names BioWave Corporation and classifies BioWave BioWraps as a Class II cutaneous electrode under 21 CFR 882.1320. The manufacturer’s own product pages and quick reference guides describe the commercial form of these garments: silver fabric electrodes built into compression wraps for specific body regions, intended for use with BioWaveHOME and BioWavePRO. [1][3][2]
The applicant and its filing record
The FDA clearance letter for K203158 is addressed to BioWave Corporation and identifies the trade name BioWave BioWraps, regulation number 21 CFR 882.1320, regulation name cutaneous electrode, Class II, and product code GXY. The letter is dated July 8, 2021, with the underlying submission dated and received October 22, 2020. The later record, K263666, carries the same product code and a substantially equivalent decision dated November 5, 2026. These two filings are the documented regulatory footprint for the BioWraps line. [3][1]
The K203158 letter lists device variants by model code, including glove style, socks style, wristbands style, elbow pads style, and knee pads style, alongside ankle sleeve, back band, and shoulder band electrodes. It also describes a knitted series of garments covering socks, gloves, sleeves, and back braces, with sizing given in small/medium and large/extra-large. That scope describes a family of wearable electrodes rather than a single wrap. [3]
Silver BioWraps as described by the manufacturer
BioWave’s Silver BioWraps page describes the products as wearable compression electrode garments that carry high-frequency neuromodulation into the body, with permanent silver fabric electrodes and targeted compression. The page states the garments are designed for use with BioWaveHOME and BioWavePRO and presents them for hard-to-reach areas and chronic pain conditions. These are the manufacturer’s characterizations of its own products. [2]
The same page states that Silver BioWraps treat up to six times the area of traditional hydrogel electrodes. That figure is a company claim about relative treatment area, not an independently verified clinical result, and it should be read as the manufacturer’s description of its electrode design. [2]
Documented garment configurations and sizing
The quick reference guides document region-specific garments. The Back BioWrap is sized by waist measurement at 28 to 37 inches for S/M and 38 to 50 inches for L/XL, with a note that 51 to 60 inches requires a Back Extender. The Thigh-Calf BioWrap is one size covering a 12 to 30 inch circumference around thigh, calf, or arm, and is described for use on the left or right thigh or calf. [4][6]
The Hand-Wrist BioWrap is sized by wrist circumference at 5.75 to 7 inches for S/M and 7 to 8.5 inches for L/XL, with a circumferential silver fabric electrode around the hand and elastic straps at the hand and wrist. The Foot-Ankle BioWrap is sized by shoe size, with S/M for women 6 to 10 and men 5 to 9, and L/XL for women 11 to 16 and men 10 to 15, and carries a circumferential electrode around the ankle. Each guide states the garment is only for use with BioWaveHOME and BioWavePRO. [7][8]
How to read the collection figures
The linked filing collection retrieved on November 20, 2026 contains one 510(k) record, K263666, and its decision count is one substantially equivalent decision. The record sample shown is the same single entry, so the sample decision count also stands at one. These figures describe the retrieved filings at that date and do not represent total company sales, total portfolio, or safety performance. [1]
Corporate location details differ across the manufacturer’s documents: one guide lists Westport, Connecticut, while another lists Norwalk, Connecticut. FDA filing correspondence addresses are regulatory contact points and are not evidence of a headquarters. Ownership, parent entities, and any brand relationships beyond the named applicant are not established by these records. [4][6][3]


